Resolve Digital Health, a Canadian developer of cannabis formulations, brands and smart devices, is pleased to announce it is collaborating with Dr. David Casarett, MD to develop the company’s treatment program for cancer patients, intended to ease pain, reduce nausea and stimulate appetite, all in conjunction with Resolve inhalers and vaporizers.
|
TORONTO, /PRNewswire/ -- Resolve Digital Health, a Canadian developer of cannabis formulations, brands and smart devices, is pleased to announce it is collaborating with Dr. David Casarett, MD to develop the company’s treatment program for cancer patients, intended to ease pain, reduce nausea and stimulate appetite, all in conjunction with Resolve inhalers and vaporizers. The program will integrate holistic medical treatments alongside medical cannabis, which will result in a highly personalized and effective level of care for patients suffering from the side effects of cancer and chemotherapy. “Resolve Digital Health intrigued me from the start because it built a system that aligns a smart, metered-dosing based vaping device with machine learning to help patients find the right dose formulation in a streamlined fashion, essentially short-circuiting the trial-and-error process,” said Dr. Casarett. “It’s important to minimize pain and discomfort for patients, and the faster we can identify what does and does not work for an individual, the more successful treatment will be.” In November 2016, Dr. Casarett gave a TED Talk based on his most recent book, “Stoned: A Doctor’s Case for Medical Marijuana,” outlining the existing evidence on medical cannabis and presenting science-based arguments for both its benefits and challenges. After determining that the plant gives patients a level of control over their treatment, he decided to focus his industry involvement with companies that are mission-driven and have an open mind for evidence. Dr. Casarett’s background lies in palliative care and health services, where he works to improve systems of care for people with serious, life-threatening illnesses. He is a Professor of Medicine at Duke University School of Medicine, and Chief of Palliative Care at Duke Health, which is consistently ranked among the best health care facilities in the United States. He has authored more than 100 articles in journals and publications, including The Journal of the American Medical Association, The New York Times, WIRED, Newsweek and Salon, among others. “Our team is excited to have Dr. Casarett come on board, and with his research-driven background, dedication to patient care, and curiosity regarding medical cannabis, he will be an incredible asset as we build out our medical programs in areas like cancer, pain, anxiety and opioid substitutes,” said Rob Adelson, CEO and Founder of Resolve. “We hope to move the needle forward on physicians’ involvement in the medical cannabis community, and look forward to compiling our data to support informed recommendations and collaborative healthcare with patients and care providers.” The first of Resolve’s family of medical cannabis vaporizers will soon be available on the market, with the objective of filling a void for consistent and standardized inhalational dosing of medical cannabis. About Resolve Digital Health Resolve Digital Health is positioned to be the leading provider of a metered dosing ecosystem for cannabis devices for the health and wellness markets. The company’s proprietary technology, apps and cloud-based health information platform address the numerous issues with currently available methods of cannabis delivery – establishing a data-driven standard of care and cutting-edge vaporizers for the cannabis industry. With over three years of research and development, the complete product ecosystem will be available in early 2019. For more information, please visit www.resolvedigitalhealth.com.
SOURCE Resolve Digital Health |
View original content:
